+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446045
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen
  • EPIRUS Biopharmaceuticals
  • Janssen Biotech
  • Momenta Pharmaceuticals
  • Samsung Bioepis
TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global tnf alpha inhibitors market.







This report focuses on the tnf alpha inhibitors market which is experiencing strong growth. The report gives a guide to the tnf alpha inhibitors market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for tnf alpha inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The TNF Alpha Inhibitors market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider tnf alpha inhibitors market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The tnf alpha inhibitors market section of the report gives context. It compares the tnf alpha inhibitors market with other segments of the tnf alpha inhibitors market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, tnf alpha inhibitors indicators comparison.

Scope


Markets Covered:


  • By Drug: Remicade (Infliximab); Enbrel (Etanercept); Humira (Adalimumab); Cimzia (Certolizumab Pegol); Simponi (Golimumab)
  • By Route Of Administration: Oral; Subcutaneous; Intravenous; Others
  • By Disease Type: Inflammatory Bowel Disease; Psoriatic Arthritis; Ulcerative Colitis (UC); Rheumatoid Arthritis; Ankylosing Spondylitis; Others

Companies Mentioned:


AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A; Novartis International AG

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global TNF Alpha Inhibitors Market

What is the estimated value of the Global TNF Alpha Inhibitors Market?

The Global TNF Alpha Inhibitors Market was estimated to be valued at $40.3 billion in 2021.

What is the growth rate of the Global TNF Alpha Inhibitors Market?

The growth rate of the Global TNF Alpha Inhibitors Market is 3.2%, with an estimated value of $45.7 billion by 2025.

What is the forecasted size of the Global TNF Alpha Inhibitors Market?

The Global TNF Alpha Inhibitors Market is estimated to be worth $45.7 billion by 2025.

Who are the key companies in the Global TNF Alpha Inhibitors Market?

Key companies in the Global TNF Alpha Inhibitors Market include AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A, Novartis International AG, Pfizer Inc., Merck & co. Inc., Janssen Biotech and Momenta Pharmaceuticals.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen
  • EPIRUS Biopharmaceuticals
  • Janssen Biotech
  • Momenta Pharmaceuticals
  • Samsung Bioepis

1. Executive Summary2. TNF Alpha Inhibitors Market Characteristics3. TNF Alpha Inhibitors Market Trends and Strategies4. Impact Of COVID-19 On TNF Alpha Inhibitors
5. TNF Alpha Inhibitors Market Size and Growth
5.1. Global TNF Alpha Inhibitors Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global TNF Alpha Inhibitors Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. TNF Alpha Inhibitors Market Segmentation
6.1. Global TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Remicade (infliximab)
  • Enbrel (etanercept)
  • Humira (adalimumab)
  • Cimzia (certolizumab pegol)
  • Simponi (golimumab)
6.2. Global TNF Alpha Inhibitors Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
6.3. Global TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Inflammatory Bowel Disease
  • Psoriatic Arthritis
  • Ulcerative Colitis (UC)
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Others

7. TNF Alpha Inhibitors Market Regional and Country Analysis
7.1. Global TNF Alpha Inhibitors Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global TNF Alpha Inhibitors Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific TNF Alpha Inhibitors Market
8.1. Asia-Pacific TNF Alpha Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China TNF Alpha Inhibitors Market
9.1. China TNF Alpha Inhibitors Market Overview
9.2. China TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India TNF Alpha Inhibitors Market
10.1. India TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan TNF Alpha Inhibitors Market
11.1. Japan TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia TNF Alpha Inhibitors Market
12.1. Australia TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia TNF Alpha Inhibitors Market
13.1. Indonesia TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea TNF Alpha Inhibitors Market
14.1. South Korea TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe TNF Alpha Inhibitors Market
15.1. Western Europe TNF Alpha Inhibitors Market Overview
15.2. Western Europe TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK TNF Alpha Inhibitors Market
16.1. UK TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany TNF Alpha Inhibitors Market
17.1. Germany TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France TNF Alpha Inhibitors Market
18.4. France TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe TNF Alpha Inhibitors Market
19.1. Eastern Europe TNF Alpha Inhibitors Market Overview
19.2. Eastern Europe TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia TNF Alpha Inhibitors Market
20.1. Russia TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America TNF Alpha Inhibitors Market
21.1. North America TNF Alpha Inhibitors Market Overview
21.2. North America TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA TNF Alpha Inhibitors Market
22.1. USA TNF Alpha Inhibitors Market Overview
22.2. USA TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America TNF Alpha Inhibitors Market
23.1. South America TNF Alpha Inhibitors Market Overview
23.2. South America TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil TNF Alpha Inhibitors Market
24.1. Brazil TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East TNF Alpha Inhibitors Market
25.1. Middle East TNF Alpha Inhibitors Market Overview
25.2. Middle East TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa TNF Alpha Inhibitors Market
26.1. Africa TNF Alpha Inhibitors Market Overview
26.2. Africa TNF Alpha Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa TNF Alpha Inhibitors Market, Segmentation by Disease Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. TNF Alpha Inhibitors Market Competitive Landscape and Company Profiles
27.1. TNF Alpha Inhibitors Market Competitive Landscape
27.2. TNF Alpha Inhibitors Market Company Profiles
27.2.1. AbbVie Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Amgen Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Johnson & Johnson Services, Inc.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. UCB S.A
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Novartis International AG
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. TNF Alpha Inhibitors Pipeline Analysis29. Key Mergers and Acquisitions in the TNF Alpha Inhibitors Market30. TNF Alpha Inhibitors Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen
  • EPIRUS Biopharmaceuticals
  • Janssen Biotech
  • Momenta Pharmaceuticals
  • Samsung Bioepis
Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A, Novartis International AG, Pfizer, Inc., Merck & co., Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals.

The global TNF alpha inhibitors market is expected to grow from $38.85 billion in 2020 to $40.33 billion in 2021 at a compound annual growth rate (CAGR) of 3.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $45.74 billion in 2025 at a CAGR of 3%.

The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-α) inhibitors by entities that manufacture TNF alpha inhibitors. TNF alpha inhibitors are a group of medicines that conquer the body’s natural response to TNF, a protein produced by white blood cells, involved in early inflammatory events. These are important treatments in the number of inflammatory conditions including spondylarthritis, psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).

The TNF alpha inhibitors market covered in this report is segmented by drug into remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), simponi (golimumab). It is also segmented by route of administration into oral, subcutaneous, intravenous, others and by disease type into inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market.

In May 2020, AbbVie Inc, a US-based biopharmaceutical company, completed the acquisition of Allergan plc for an amount of $63 billion. The acquisition is expected to expand and diversify AbbVie Inc’s revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology.

The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services Inc.
  • UCB S.A
  • Novartis International AG
  • Pfizer Inc.
  • Merck & co. Inc.
  • Janssen Biotech
  • Ablynx
  • Momenta Pharmaceuticals
  • Celgene Corporation
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Zydus Cadila
  • HanAll Biopharma
  • AryoGen Biopharma
  • LG Life Sciences
  • Samsung Bioepis
  • Bionovis
  • Celltrion Healthcare
  • CASI Pharmaceuticals
  • EPIRUS Biopharmaceuticals
  • HanAll Biopharma
  • Intas Pharmaceuticals
  • LEO Pharma
  • MedImmune
  • Momenta Pharmaceuticals
  • Reliance Life Sciences
  • Sandoz
  • Biogen
  • AstraZeneca
Note: Product cover images may vary from those shown

Loading
LOADING...